Europäischer Krebsbehandlungsmarktbericht – Branchentrends Und Prognose Bis 2029

Europe Cancer Treatment Market

Marktgröße in Milliarden USD

CAGR : 11.20 %

Prognosezeitraum	2022 –2029
Marktgröße (Basisjahr)	USD 75,654.50 Million
Marktgröße (Prognosejahr)	USD 172,492.46 Million
CAGR	11.20 %
Wichtige Marktteilnehmer	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Anfrage zur Freischaltung

>Europäischer Markt für Krebsbehandlungen, nach Krebsart (Brustkrebs, Dickdarmkrebs mit Lebermetastasen, Lungenkarzinom, Prostatakrebs, Eierstockkrebs, Kopf-Hals-Krebs, Bauchspeicheldrüsenkrebs, Glioblastom, Nierenzellkarzinom, anaplastisches Schilddrüsenkarzinom, Sarkom und andere), Behandlung (Medikamente, zielgerichtete Therapien, Strahlentherapie, Chirurgie und andere), Verabreichungsweg (injizierbar, oral und andere), Endverbraucher (Krankenhäuser, Fachkliniken), Land (Deutschland, Frankreich, Großbritannien, Italien, Spanien, Russland, Türkei, Belgien, Ungarn, Niederlande, Schweiz, Litauen, Österreich, Norwegen, Irland, Polen und übriges Europa) – Branchentrends und Prognose bis 2029

Marktanalyse und Einblicke : Europäischer Markt für Krebsbehandlungen

Der europäische Markt für Krebsbehandlungen dürfte im Prognosezeitraum 2022 bis 2029 ein Marktwachstum verzeichnen. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum 2022 bis 2029 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 11,2 % wächst und von 75.654,50 Millionen USD im Jahr 2021 auf 172.492,46 Millionen USD im Jahr 2029 ansteigen dürfte. Die hohe Verbreitung von Krebs und die zunehmenden F&E-Aktivitäten für seine wirksame Anwendung dürften die Haupttreiber sein, die die Marktnachfrage im Prognosezeitraum ankurbeln.

Krebs ist eine Krankheit, bei der einige Körperzellen unkontrolliert wachsen und sich schließlich in andere Körperteile ausbreiten. Der Krebstumor breitet sich in benachbarte Gewebe aus und kann sich an entfernte Stellen im Körper ausbreiten, um einen neuen Tumor zu bilden. Dieser Prozess wird als Metastasierung bezeichnet. Der Krebstumor wird auch als bösartiger Tumor bezeichnet. Der gutartige Tumor dringt nicht in benachbarte Gewebe ein, und wenn er entfernt wird, wachsen gutartige Tumore normalerweise nicht nach, während dies bei Krebstumoren manchmal der Fall ist.

Es gibt mehr als hundert Krebsarten. Einige Krebsarten, die in bestimmten Zelltypen beginnen, sind unter anderem Karzinom, Sarkom, Leukämie, Lymphom und Multiples Myelom. Abhängig von der Krebsart stehen viele Arten der Krebsbehandlung zur Verfügung. Die Krebsbehandlung umfasst unter anderem Biomarkertests zur Krebsbehandlung, Chemotherapie, Hormontherapie, Hyperthermie, Immuntherapie, photodynamische Therapie, Strahlentherapie, Chirurgie, Stammzelltransplantation und zielgerichtete Therapien.

Laut GLOBOCAN wurden im Jahr 2020 weltweit 19.292.789 neue Krebsfälle festgestellt. Die meisten Fälle von Brustkrebs wurden festgestellt. Daher wird erwartet, dass die hohe Prävalenz von Krebs, Initiativen der Regierung zur Sensibilisierung und Früherkennung von Krebs sowie laufende klinische Studien das Wachstum des Marktes ankurbeln werden.

Die hohe Krebsrate und die zunehmenden staatlichen Initiativen dürften das Marktwachstum ankurbeln. Die hohen Kosten der Krebsbehandlung könnten das Marktwachstum jedoch bremsen. Die strategischen Initiativen der wichtigsten Marktteilnehmer dürften dem Markt Wachstumsmöglichkeiten eröffnen. Die Nebenwirkungen der Medikamente könnten das Marktwachstum jedoch bremsen.

Der Bericht zum europäischen Krebsbehandlungsmarkt liefert Einzelheiten zu Marktanteilen, neuen Entwicklungen und dem Einfluss inländischer und lokaler Marktteilnehmer, analysiert Chancen in Bezug auf neue Einnahmequellen, Änderungen der Marktvorschriften, Produktzulassungen, strategische Entscheidungen, Produkteinführungen, geografische Expansionen und technologische Innovationen auf dem Markt. Um die Analyse und das Marktszenario zu verstehen, kontaktieren Sie uns für ein Analyst Briefing. Unser Team hilft Ihnen dabei, eine umsatzwirksame Lösung zu entwickeln, mit der Sie Ihr gewünschtes Ziel erreichen.

Marktumfang und Marktgröße für Krebsbehandlungen in Europa

Der europäische Markt für Krebsbehandlungen ist in vier wichtige Segmente unterteilt, die auf Krebsart, Behandlung, Verabreichungsweg und Endverbraucher basieren. Das Wachstum zwischen den Segmenten hilft Ihnen, Nischenwachstumsbereiche und Strategien zur Marktbearbeitung zu analysieren und Ihre wichtigsten Anwendungsbereiche und die Unterschiede in Ihren Zielmärkten zu bestimmen.

Auf der Grundlage der Krebsart ist der europäische Markt für Krebsbehandlungen in Brustkrebs, Dickdarmkrebs mit Lebermetastasen, Lungenkarzinom, Prostatakrebs, Eierstockkrebs, Kopf-Hals-Krebs, Bauchspeicheldrüsenkrebs, Glioblastom, Nierenzellkarzinom, anaplastisches Schilddrüsenkarzinom und Sarkom unterteilt. Im Jahr 2022 wird das Brustkrebssegment voraussichtlich den Markt dominieren, da verschiedene Aufklärungskampagnen zur Früherkennung und Behandlung von Brustkrebs gestartet werden.
Auf der Grundlage der Behandlung ist der europäische Markt für Krebsbehandlungen in Medikamente, zielgerichtete Therapien, Strahlentherapie , Chirurgie und andere unterteilt. Im Jahr 2022 wird das Medikamentensegment voraussichtlich den Markt dominieren, da verschiedene Arten von Medikamenten zur Behandlung von Krebs auf den Markt kommen.
Auf der Grundlage der Verabreichungsmethode ist der europäische Markt für Krebsbehandlungen in injizierbare, orale und andere Mittel unterteilt. Im Jahr 2022 wird das injizierbare Segment voraussichtlich den Markt dominieren, da die meisten Krebserkrankungen in injizierbarer Form behandelt werden können.
Auf der Grundlage des Endverbrauchers ist der europäische Markt für Krebsbehandlungen in Krankenhäuser und Fachkliniken unterteilt. Im Jahr 2022 wird das Krankenhaussegment voraussichtlich den Markt dominieren, da auf dem Markt fortschrittliche Technologien zur Krebsbehandlung verfügbar sind.

Europa: Markt für Krebsbehandlungen – Länderebene-Analyse

Der europäische Markt für Krebsbehandlungen wird analysiert und Informationen zur Marktgröße werden nach Geografie, Krebsart, Behandlung, Verabreichungsweg und Endverbraucher bereitgestellt.

Zu den im europäischen Marktbericht für Krebsbehandlungen abgedeckten Ländern zählen unter anderem Deutschland, Frankreich, Großbritannien, Italien, Spanien, Russland, die Türkei, Belgien, Ungarn, die Niederlande, die Schweiz, Litauen, Österreich, Norwegen, Irland, Polen und der Rest von Europa.

Europa wird im Prognosezeitraum voraussichtlich mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 11,2 % wachsen, ebenso wie die europäischen Länder. Die Krebsrate ist hoch und die Menschen sind sich einer Frühdiagnose immer bewusster. Die Verbesserung der Gesundheitsinfrastruktur wird voraussichtlich das Wachstum des europäischen Marktes für Krebsbehandlungen vorantreiben. Deutschland wird voraussichtlich den europäischen Markt dominieren, da immer mehr Krebsmedikamente zugelassen werden.

Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, demografische Daten des Landes, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Auch die Präsenz und Verfügbarkeit europäischer Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle werden bei der Bereitstellung einer Prognoseanalyse der Länderdaten berücksichtigt.

Das Vorhandensein fortschrittlicher Technologien und strategischer Initiativen der Akteure schaffen neue Möglichkeiten auf dem europäischen Markt für Krebsbehandlungen

Der europäische Markt für Krebsbehandlungen bietet Ihnen außerdem eine detaillierte Marktanalyse für das Wachstum jedes Landes in einer bestimmten Branche mit Produktverkäufen, den Auswirkungen von Fortschritten auf dem Markt und Änderungen der regulatorischen Szenarien mit ihrer Unterstützung für den Markt für Krebsbehandlungen. Die Daten sind für den historischen Zeitraum 2011 bis 2020 verfügbar.

Wettbewerbsumfeld und Marktanteilsanalyse für Krebsbehandlungen in Europa

Die Wettbewerbslandschaft des europäischen Krebsbehandlungsmarktes liefert Einzelheiten nach Wettbewerbern. Die enthaltenen Einzelheiten sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produkttestpipelines, Produktzulassungen, Patente, Produktbreite und -umfang, Anwendungsdominanz, Technologie-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens in Bezug auf den europäischen Krebsbehandlungsmarkt.

Zu den wichtigsten Unternehmen auf dem europäischen Markt für Krebsbehandlungen zählen unter anderem Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd., Clegen, AbbVie, Inc., Pfizer, Inc. und Novartis AG. DBMR-Analysten kennen die Stärken der Konkurrenz und erstellen für jeden Wettbewerber eine separate Wettbewerbsanalyse.

Die strategischen Initiativen der Marktteilnehmer und neue technologische Fortschritte in der Krebsbehandlung schließen die Lücke zwischen verschiedenen Behandlungsmethoden.

Zum Beispiel,

Im Januar 2020 gab die Novartis AG die Übernahme des Arzneimittelherstellers bekannt. Diese Übernahme bot eine neue Möglichkeit, die geografische Präsenz des Unternehmens weltweit auszubauen. Darüber hinaus trug sie zur Erweiterung des Produktportfolios des Unternehmens bei.

Kooperationen, Joint Ventures und andere Strategien der Marktteilnehmer stärken die Position des Unternehmens im Markt für Krebsbehandlungen, was dem Unternehmen auch dabei hilft, sein Angebot für den europäischen Markt für Krebsbehandlungen zu verbessern.

SKU-67333

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Klicken Sie auf das Bild, um es zu vergrößern

Interaktives Datenanalyse-Dashboard
Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
Zugriff für Research-Analysten für Anpassungen und Abfragen
Konkurrenzanalyse mit interaktivem Dashboard
Aktuelle Nachrichten, Updates und Trendanalyse
Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung

Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CANCER TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 EPIDEMOLOGY

6 EUROPE CANCER TREATMENT MARKET: REGULATORY SCENARIO

6.1 TIMELINE TO APPROVE A DRUG

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING CANCER BURDEN WORLDWIDE

7.1.2 GROWING GERIATRIC POPULATION

7.1.3 AVAILABILITY OF DIFFERENT TYPES OF TARGETED THERAPIES

7.1.4 RISING NUMBER OF FDA APPROVAL

7.1.5 GROWING R&D ACTIVITIES

7.2 RESTRAINTS

7.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS

7.2.2 HIGH COST OF CANCER TREATMENT

7.2.3 LACK OF EARLY DETECTION

7.3 OPPORTUNITIES

7.3.1 STRATEGIC DEVELOPMENT AMONG MAJOR PLAYERS

7.3.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS

7.3.3 RISING EXPENDITURE ON CANCER TREATMENT

7.4 CHALLENGES

7.4.1 PATENT EXPIRY OF DRUGS

8 EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE

8.1 OVERVIEW

8.2 BREAST CANCER

8.3 COLORECTAL CANCER WITH LIVER METASTASES

8.4 LUNG CARCINOMA

8.5 PROSTATE CANCER

8.6 OVARIAN CANCER

8.7 HEAD-AND-NECK CANCER

8.8 PANCREATIC CANCER

8.9 GLIOBLASTOMA

8.1 RENAL CELL CARCINOMA

8.11 ANAPLASTIC THYROID CARCINOMA

8.12 SARCOMA

9 EUROPE CANCER TREATMENT MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 MEDICATION

9.2.1 BY DRUG TYPE

9.2.1.1 lung carcinoma

9.2.1.1.1 Nivolumab (Opdivo)

9.2.1.1.2 Bevacizumab (Avastin)

9.2.1.1.3 Crizotinib (Xalkori)

9.2.1.1.4 Erlotinib (Tarceva)

9.2.1.1.5 Gefitinib (Iressa)

9.2.1.1.6 Afatinib Dimaleate (Gilotrif)

9.2.1.1.7 Ceritinib (Ldk378/Zykadia)

9.2.1.1.8 Ramucirumab (Cyramza)

9.2.1.1.9 others

9.2.1.2 Colorectal Cancer with Liver Metastases

9.2.1.2.1 Nivolumab (Opdivo)

9.2.1.2.2 Cetuximab (Erbitux)

9.2.1.2.3 Panitumumab (Vectibix)

9.2.1.2.4 Bevacizumab (Avastin)

9.2.1.2.5 Ziv-Aflibercept (Zaltrap)

9.2.1.2.6 Regorafenib (Stivarga)

9.2.1.2.7 Ramucirumab (Cyramza)

9.2.1.2.8 Ipilimumab (Yervoy)

9.2.1.2.9 Encorafenib (Braftovi)

9.2.1.2.10 Pembrolizumab (Keytruda)

9.2.1.2.11 others

9.2.1.3 ovarian cancer

9.2.1.3.1 Bevacizumab (Avastin)

9.2.1.3.2 Olaparib (Lynparza)

9.2.1.3.3 Rucaparib Camsylate (Rubraca)

9.2.1.3.4 Niraparib Tosylate Monohydrate (Zejula)

9.2.1.3.5 others

9.2.1.4 head-and-neck cancer

9.2.1.4.1 Cetuximab (Erbitux)

9.2.1.4.2 Pembrolizumab (Keytruda)

9.2.1.4.3 Nivolumab (Opdivo)

9.2.1.4.4 others

9.2.1.5 renal cell carcinoma

9.2.1.5.1 Nivolumab (Opdivo)

9.2.1.5.2 Bevacizumab (Avastin)

9.2.1.5.3 Sorafenib (Nexavar)

9.2.1.5.4 Sunitinib (Sutent)

9.2.1.5.5 Pazopanib (Votrient)

9.2.1.5.6 Temsirolimus (Torisel)

9.2.1.5.7 Everolimus (Afinitor)

9.2.1.5.8 Axitinib (Inlyta)

9.2.1.5.9 Cabozantinib (Cabometyx)

9.2.1.5.10 others

9.2.1.6 anaplastic thyroid carcinoma

9.2.1.6.1 Cabozantinib (Cometriq)

9.2.1.6.2 Vandetanib (Caprelsa)

9.2.1.6.3 Sorafenib (Nexavar)

9.2.1.6.4 Lenvatinib Mesylate (Lenvima)

9.2.1.6.5 Trametinib (Mekinist)

9.2.1.6.6 Dabrafenib (Tafinlar)

9.2.1.6.7 Selpercatinib (Retevmo)

9.2.1.6.8 Pralsetinib (Gavreto)

9.2.1.6.9 others

9.2.1.7 breast cancer

9.2.1.7.1 Everolimus (Afinitor)

9.2.1.7.2 Tamoxifen (Nolvadex)

9.2.1.7.3 Trastuzumab (Herceptin)

9.2.1.7.4 Fulvestrant (Faslodex)

9.2.1.7.5 Anastrozole (Arimidex)

9.2.1.7.6 Exemestane (Aromasin)

9.2.1.7.7 Letrozole (Femara)

9.2.1.7.8 Pertuzumab (Perjeta)

9.2.1.7.9 Palbociclib (Ibrance)

9.2.1.7.10 Ribociclib (Kisqali)

9.2.1.7.11 Tosylate (Talzenna)

9.2.1.7.12 Pembrolizumab (Keytruda)

9.2.1.7.13 Margetuximab-Cmkb (Margenza)

9.2.1.7.14 others

9.2.1.8 prostate cancer

9.2.1.8.1 Cabazitaxel (Jevtana)

9.2.1.8.2 Enzalutamide (Xtandi)

9.2.1.8.3 Abiraterone Acetate (Zytiga)

9.2.1.8.4 Radium 223 Dichloride (Xofigo)

9.2.1.8.5 Apalutamide (Erleada)

9.2.1.8.6 Darolutamide (Nubeqa)

9.2.1.8.7 Rucaparib Camsylate (Rubraca)

9.2.1.8.8 Olaparib (Lynparza)

9.2.1.8.9 others

9.2.1.9 pancreatic cancer

9.2.1.9.1 Erlotinib (Tarceva)

9.2.1.9.2 Everolimus (Afinitor)

9.2.1.9.3 Sunitinib (Sutent)

9.2.1.9.4 Olaparib (Lynparza)

9.2.1.9.5 Belzutifan (Welireg)

9.2.1.9.6 others

9.2.1.10 glioblastoma

9.2.1.10.1 Bevacizumab (Avastin)

9.2.1.10.2 Everolimus (Afinitor)

9.2.1.10.3 Belzutifan (Welireg)

9.2.1.10.4 others

9.2.1.11 sarcoma

9.2.1.11.1 Cosmegen (Dactinomycin)

9.2.1.11.2 Dactinomycin

9.2.1.11.3 Doxorubicin Hydrochloride

9.2.1.11.4 Eribulin Mesylate

9.2.1.11.5 Gleevec (Imatinib Mesylate)

9.2.1.11.6 Halaven (Eribulin Mesylate)

9.2.1.11.7 Imatinib Mesylate

9.2.1.11.8 Pazopanib Hydrochloride

9.2.1.11.9 Tazemetostat Hydrobromide

9.2.1.11.10 Tazverik (Tazemetostat Hydrobromide)

9.2.1.11.11 Trabectedin

9.2.1.11.12 Votrient (Pazopanib Hydrochloride)

9.2.1.11.13 Yondelis (Trabectedin)

9.2.1.11.14 others

9.2.2 BY VACCINES

9.2.2.1 Cervarix

9.2.2.2 Gardasil

9.2.2.3 Gardasil-9

9.2.2.4 Hepatitis B (Hbv) Vaccine (Heplisav-B)

9.2.2.5 Sipuleucel-T (Provenge)

9.2.2.6 others

9.3 RADIOTHERAPY

9.3.1 EXTERNAL BEAM RADIATION THERAPY

9.3.1.1 Three -Dimensional Confromal Radiation Therapy (3-D CRT)

9.3.1.2 Proton Therapy

9.3.1.3 Intensity-Modulated Radiation Therapy (IMRT)

9.3.1.4 Image-Guided Radiation Therapy (IGRT)

9.3.1.5 Tomotherapy

9.3.1.6 Stereotactic Radiosurgery

9.3.1.7 Stereotactic Body Radiation Therapy (SRT)

9.3.1.8 Intraoperative Radiation Therapy

9.3.1.9 others

9.3.2 INTERNAL RADIATION THERAPY (BRACHYTHERAPY)

9.3.2.1 low-dose-rate (LDR) brachytherapy

9.3.2.2 high-dose-rate (HDR) brachytherapy

9.3.3 SYSTEMIC RADIATION THERAPY

9.3.3.1 peptide receptor radionuclide therapy (PRRT)

9.3.3.2 others

9.4 SURGERY

9.4.1 PAROTIDECTOMY

9.4.2 ENDOSCOPIC SURGERY

9.4.3 NECK DISSECTION

9.4.4 RECONSTRUCTIVE SURGERY

9.4.5 OTHERS

9.5 TARGETED THERAPIES

9.5.1 SMALL MOLECULES

9.5.1.1 tyrosine & serine/threonine kinases

9.5.1.1.1 imatinib (gleevec)

9.5.1.1.2 gefitinib (iressa)

9.5.1.1.3 erlotinib (tarceva)

9.5.1.1.4 sunitinib (sutent)

9.5.1.1.5 perifosine

9.5.1.1.6 others

9.5.1.2 proteosomes

9.5.1.2.1 bortezomib (velcade)

9.5.1.2.2 carfilzomib (kyprolis)

9.5.1.2.3 marizomib

9.5.1.3 MMPS and HSPS

9.5.1.3.1 batimastat

9.5.1.3.2 neovastat

9.5.1.3.3 prinomastat

9.5.1.3.4 rebimastat

9.5.1.3.5 ganetespib

9.5.1.3.6 others

9.5.1.4 apoptosis

9.5.1.4.1 obatoclax

9.5.1.4.2 navitoclax

9.5.1.4.3 others

9.5.2 IMMUNOTHERAPY

9.5.2.1 immune checkpoint inhibitors

9.5.2.2 T-cell transfer therapy

9.5.2.2.1 TIL therapy

9.5.2.2.2 car T-cell therapy

9.5.2.2.3 by product

9.5.2.2.3.1 tisagenlecleucel (kymriah)

9.5.2.2.3.2 axicabtagene ciloleucel (yescarta)

9.5.2.2.3.3 brexucabtagene autoleucel (tecartus)

9.5.2.2.3.4 others

9.5.2.2.4 by technology

9.5.2.2.4.1 autologous

9.5.2.2.4.2 allogeneic

9.5.2.3 monoclonal antibodies

9.5.2.3.1 rituximab

9.5.2.3.2 blinatumomab (blincyto)

9.5.2.3.3 others

9.5.2.4 immune system modulators

9.5.2.4.1 cytokines

9.5.2.4.2 interferons (INFS)

9.5.2.4.3 interleukins (ILS)

9.5.2.4.4 hematopoietic growth factors

9.5.2.4.5 BCG

9.5.2.4.6 immunomodulatory drugs/biological response modifiers

9.5.2.4.7 thalidomide (thalomid)

9.5.2.4.8 lenalidomide (revlimid)

9.5.2.4.9 pomalidomide (pomalyst)

9.5.2.4.10 imiquimod (aldara, zyclara)

9.5.2.4.11 OTHERS

9.5.2.5 treatment vaccines

9.5.2.6 others

9.5.3 HORMONAL THERAPY

9.5.3.1 signal transduction inhibitors

9.5.3.2 gene expression modulators

9.5.3.3 apoptosis inducers

9.5.3.4 angiogenesis inhibitors

9.5.3.5 gene therapy

9.5.3.6 others

9.6 OTHERS

10 EUROPE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 INJECTABLE

10.3 ORAL

10.4 OTHERS

11 EUROPE CANCER TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 SPECIALTY CLINICS

12 EUROPE CANCER TREATMENT MARKET, BY REGION

12.1 EUROPE

12.1.1 GERMANY

12.1.2 FRANCE

12.1.3 U.K.

12.1.4 ITALY

12.1.5 SPAIN

12.1.6 NETHERLANDS

12.1.7 DENMARK

12.1.8 SWITZERLAND

12.1.9 SWEDEN

12.1.10 AUSTRIA

12.1.11 NORWAY

12.1.12 HUNGARY

12.1.13 GREECE

12.1.14 IRELAND

12.1.15 POLAND

12.1.16 REST OF EUROPE

13 EUROPE CANCER TREATMENT MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 QUESTIONNAIRE

15 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 DIFFERENCES IN APPROVAL TIMES BETWEEN EMEA AND FDA FOR SELECTED TARGETED THERAPIES SINCE 2001

TABLE 2 NEW CANCER CASES, AGES 85+ IN THE U.S.

TABLE 3 DEATH CAUSES DUE TO CANCER, AGES 85+ IN THE U.S.

TABLE 4 HERE ARE SOME STATISTICS RELATED TO THE TREATMENT COST:

TABLE 5 EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 6 EUROPE BREAST CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 EUROPE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE SARCOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 EUROPE MEDICATION IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 EUROPE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 EUROPE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 24 EUROPE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 25 EUROPE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 26 EUROPE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 EUROPE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 28 EUROPE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 29 EUROPE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 30 EUROPE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 EUROPE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 32 EUROPE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 33 EUROPE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 EUROPE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 EUROPE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 36 EUROPE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 37 EUROPE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 38 EUROPE SURGERY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 EUROPE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 40 EUROPE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 EUROPE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 42 EUROPE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 EUROPE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 EUROPE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 EUROPE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 EUROPE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 EUROPE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 48 EUROPE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 49 EUROPE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 50 EUROPE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 EUROPE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 EUROPE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 EUROPE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 EUROPE OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 55 EUROPE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 56 EUROPE INJECTABLE IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 57 EUROPE ORAL IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 58 EUROPE OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 59 EUROPE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 60 EUROPE HOSPITALS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 61 EUROPE SPECIALTY CLINICS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 62 EUROPE CANCER TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 63 EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 64 EUROPE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 65 EUROPE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 EUROPE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 67 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 68 EUROPE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 69 EUROPE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 70 EUROPE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 71 EUROPE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 72 EUROPE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 EUROPE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 EUROPE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 EUROPE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 EUROPE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 EUROPE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 EUROPE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 EUROPE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 EUROPE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 EUROPE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 EUROPE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 EUROPE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 84 EUROPE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 85 EUROPE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 86 EUROPE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 87 EUROPE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 88 EUROPE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 89 EUROPE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 90 EUROPE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 91 EUROPE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 92 EUROPE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 93 EUROPE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 94 EUROPE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 95 EUROPE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 EUROPE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 97 EUROPE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 98 EUROPE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 99 GERMANY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 100 GERMANY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 101 GERMANY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 GERMANY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 GERMANY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 GERMANY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 GERMANY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 106 GERMANY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 107 GERMANY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 108 GERMANY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 109 GERMANY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 110 GERMANY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 111 GERMANY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 112 GERMANY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 113 GERMANY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 114 GERMANY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 115 GERMANY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 116 GERMANY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 117 GERMANY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 118 GERMANY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 119 GERMANY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 120 GERMANY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 121 GERMANY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 122 GERMANY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 123 GERMANY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 124 GERMANY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 125 GERMANY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 126 GERMANY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 127 GERMANY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 128 GERMANY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 129 GERMANY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 130 GERMANY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 131 GERMANY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 132 GERMANY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 133 GERMANY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 134 GERMANY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 135 FRANCE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 136 FRANCE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 137 FRANCE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 138 FRANCE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 139 FRANCE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 140 FRANCE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 141 FRANCE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 142 FRANCE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 143 FRANCE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 144 FRANCE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 145 FRANCE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 146 FRANCE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 147 FRANCE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 148 FRANCE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 149 FRANCE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 150 FRANCE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 151 FRANCE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 152 FRANCE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 153 FRANCE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 154 FRANCE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 155 FRANCE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 156 FRANCE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 157 FRANCE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 158 FRANCE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 159 FRANCE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 160 FRANCE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 161 FRANCE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 162 FRANCE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 163 FRANCE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 164 FRANCE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 165 FRANCE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 166 FRANCE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 167 FRANCE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 168 FRANCE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 169 FRANCE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 170 FRANCE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 171 U.K. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 172 U.K. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 173 U.K. MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 174 U.K. BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 175 U.K. LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 176 U.K. COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 177 U.K. OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 178 U.K. HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 179 U.K. RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 180 U.K. ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 181 U.K. BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 182 U.K. PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 183 U.K. PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 184 U.K. GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 185 U.K. SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 186 U.K. BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 187 U.K. RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 188 U.K. EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 189 U.K. INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 190 U.K. SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 191 U.K. SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 192 U.K. TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 193 U.K. SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 194 U.K. TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 195 U.K. PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 196 U.K. MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 197 U.K. APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 198 U.K. IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 199 U.K. T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 200 U.K. BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 201 U.K. BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 202 U.K. MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 203 U.K. IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 204 U.K. HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 205 U.K. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 206 U.K. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 207 ITALY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 208 ITALY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 209 ITALY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 210 ITALY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 211 ITALY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 212 ITALY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 213 ITALY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 214 ITALY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 215 ITALY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 216 ITALY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 217 ITALY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 218 ITALY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 219 ITALY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 220 ITALY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 221 ITALY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 222 ITALY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 223 ITALY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 224 ITALY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 225 ITALY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 226 ITALY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 227 ITALY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 228 ITALY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 229 ITALY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 230 ITALY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 231 ITALY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 232 ITALY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 233 ITALY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 234 ITALY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 235 ITALY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 236 ITALY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 237 ITALY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 238 ITALY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 239 ITALY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 240 ITALY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 241 ITALY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 242 ITALY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 243 SPAIN CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 244 SPAIN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 245 SPAIN MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 246 SPAIN BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 247 SPAIN LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 248 SPAIN COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 249 SPAIN OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 250 SPAIN HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 251 SPAIN RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 252 SPAIN ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 253 SPAIN BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 254 SPAIN PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 255 SPAIN PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 256 SPAIN GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 257 SPAIN SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 258 SPAIN BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 259 SPAIN RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 260 SPAIN EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 261 SPAIN INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 262 SPAIN SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 263 SPAIN SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 264 SPAIN TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 265 SPAIN SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 266 SPAIN TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 267 SPAIN PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 268 SPAIN MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 269 SPAIN APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 270 SPAIN IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 271 SPAIN T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 272 SPAIN BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 273 SPAIN BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 274 SPAIN MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 275 SPAIN IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 276 SPAIN HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 277 SPAIN CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 278 SPAIN CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 279 NETHERLANDS CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 280 NETHERLANDS CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 281 NETHERLANDS MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 282 NETHERLANDS BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 283 NETHERLANDS LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 284 NETHERLANDS COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 285 NETHERLANDS OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 286 NETHERLANDS HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 287 NETHERLANDS RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 288 NETHERLANDS ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 289 NETHERLANDS BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 290 NETHERLANDS PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 291 NETHERLANDS PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 292 NETHERLANDS GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 293 NETHERLANDS SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 294 NETHERLANDS BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 295 NETHERLANDS RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 296 NETHERLANDS EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 297 NETHERLANDS INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 298 NETHERLANDS SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 299 NETHERLANDS SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 300 NETHERLANDS TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 301 NETHERLANDS SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 302 NETHERLANDS TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 303 NETHERLANDS PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 304 NETHERLANDS MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 305 NETHERLANDS APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 306 NETHERLANDS IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 307 NETHERLANDS T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 308 NETHERLANDS BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 309 NETHERLANDS BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 310 NETHERLANDS MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 311 NETHERLANDS IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 312 NETHERLANDS HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 313 NETHERLANDS CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 314 NETHERLANDS CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 315 DENMARK CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 316 DENMARK CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 317 DENMARK MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 318 DENMARK BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 319 DENMARK LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 320 DENMARK COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 321 DENMARK OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 322 DENMARK HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 323 DENMARK RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 324 DENMARK ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 325 DENMARK BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 326 DENMARK PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 327 DENMARK PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 328 DENMARK GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 329 DENMARK SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 330 DENMARK BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 331 DENMARK RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 332 DENMARK EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 333 DENMARK INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 334 DENMARK SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 335 DENMARK SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 336 DENMARK TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 337 DENMARK SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 338 DENMARK TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 339 DENMARK PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 340 DENMARK MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 341 DENMARK APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 342 DENMARK IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 343 DENMARK T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 344 DENMARK BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 345 DENMARK BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 346 DENMARK MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 347 DENMARK IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 348 DENMARK HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 349 DENMARK CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 350 DENMARK CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 351 SWITZERLAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 352 SWITZERLAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 353 SWITZERLAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 354 SWITZERLAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 355 SWITZERLAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 356 SWITZERLAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 357 SWITZERLAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 358 SWITZERLAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 359 SWITZERLAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 360 SWITZERLAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 361 SWITZERLAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 362 SWITZERLAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 363 SWITZERLAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 364 SWITZERLAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 365 SWITZERLAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 366 SWITZERLAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 367 SWITZERLAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 368 SWITZERLAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 369 SWITZERLAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 370 SWITZERLAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 371 SWITZERLAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 372 SWITZERLAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 373 SWITZERLAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 374 SWITZERLAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 375 SWITZERLAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 376 SWITZERLAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 377 SWITZERLAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 378 SWITZERLAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 379 SWITZERLAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 380 SWITZERLAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 381 SWITZERLAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 382 SWITZERLAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 383 SWITZERLAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 384 SWITZERLAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 385 SWITZERLAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 386 SWITZERLAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 387 SWEDEN CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 388 SWEDEN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 389 SWEDEN MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 390 SWEDEN BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 391 SWEDEN LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 392 SWEDEN COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 393 SWEDEN OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 394 SWEDEN HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 395 SWEDEN RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 396 SWEDEN ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 397 SWEDEN BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 398 SWEDEN PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 399 SWEDEN PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 400 SWEDEN GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 401 SWEDEN SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 402 SWEDEN BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 403 SWEDEN RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 404 SWEDEN EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 405 SWEDEN INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 406 SWEDEN SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 407 SWEDEN SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 408 SWEDEN TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 409 SWEDEN SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 410 SWEDEN TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 411 SWEDEN PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 412 SWEDEN MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 413 SWEDEN APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 414 SWEDEN IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 415 SWEDEN T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 416 SWEDEN BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 417 SWEDEN BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 418 SWEDEN MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 419 SWEDEN IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 420 SWEDEN HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 421 SWEDEN CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 422 SWEDEN CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 423 AUSTRIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 424 AUSTRIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 425 AUSTRIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 426 AUSTRIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 427 AUSTRIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 428 AUSTRIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 429 AUSTRIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 430 AUSTRIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 431 AUSTRIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 432 AUSTRIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 433 AUSTRIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 434 AUSTRIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 435 AUSTRIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 436 AUSTRIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 437 AUSTRIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 438 AUSTRIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 439 AUSTRIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 440 AUSTRIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 441 AUSTRIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 443 AUSTRIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 444 AUSTRIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 445 AUSTRIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 446 AUSTRIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 447 AUSTRIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 448 AUSTRIA PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 449 AUSTRIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 450 AUSTRIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 451 AUSTRIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 452 AUSTRIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 453 AUSTRIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 454 AUSTRIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 455 AUSTRIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 456 AUSTRIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 457 AUSTRIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 458 AUSTRIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 459 AUSTRIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 460 NORWAY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 461 NORWAY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 462 NORWAY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 463 NORWAY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 464 NORWAY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 465 NORWAY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 466 NORWAY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 467 NORWAY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 468 NORWAY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 469 NORWAY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 470 NORWAY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 471 NORWAY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 472 NORWAY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 473 NORWAY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 474 NORWAY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 475 NORWAY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 476 NORWAY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 477 NORWAY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 478 NORWAY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 479 NORWAY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 480 NORWAY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 481 NORWAY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 482 NORWAY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 483 NORWAY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 484 NORWAY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 485 NORWAY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 486 NORWAY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 487 NORWAY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 488 NORWAY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 489 NORWAY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 490 NORWAY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 491 NORWAY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 492 NORWAY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 493 NORWAY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 494 NORWAY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 495 NORWAY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 496 HUNGARY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 497 HUNGARY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 498 HUNGARY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 499 HUNGARY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 500 HUNGARY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 501 HUNGARY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 502 HUNGARY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 503 HUNGARY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 504 HUNGARY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 505 HUNGARY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 506 HUNGARY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 507 HUNGARY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 508 HUNGARY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 509 HUNGARY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 510 HUNGARY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 511 HUNGARY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 512 HUNGARY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 513 HUNGARY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 514 HUNGARY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 515 HUNGARY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 516 HUNGARY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 517 HUNGARY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 518 HUNGARY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 519 HUNGARY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 520 HUNGARY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 521 HUNGARY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 522 HUNGARY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 523 HUNGARY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 524 HUNGARY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 525 HUNGARY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 526 HUNGARY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 527 HUNGARY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 528 HUNGARY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 529 HUNGARY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 530 HUNGARY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 531 HUNGARY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 532 GREECE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 533 GREECE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 534 GREECE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 535 GREECE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 536 GREECE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 537 GREECE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 538 GREECE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 539 GREECE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 540 GREECE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 541 GREECE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 542 GREECE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 543 GREECE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 544 GREECE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 545 GREECE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 546 GREECE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 547 GREECE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 548 GREECE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 549 GREECE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 550 GREECE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 551 GREECE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 552 GREECE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 553 GREECE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 554 GREECE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 555 GREECE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 556 GREECE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 557 GREECE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 558 GREECE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 559 GREECE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 560 GREECE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 561 GREECE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 562 GREECE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 563 GREECE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 564 GREECE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 565 GREECE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 566 GREECE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 567 GREECE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 568 IRELAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 569 IRELAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 570 IRELAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 571 IRELAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 572 IRELAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 573 IRELAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 574 IRELAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 575 IRELAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 576 IRELAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 577 IRELAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 578 IRELAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 579 IRELAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 580 IRELAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 581 IRELAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 582 IRELAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 583 IRELAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 584 IRELAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 585 IRELAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 586 IRELAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 587 IRELAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 588 IRELAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 589 IRELAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 590 IRELAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 591 IRELAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 592 IRELAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 593 IRELAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 594 IRELAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 595 IRELAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 596 IRELAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 597 IRELAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 598 IRELAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 599 IRELAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 600 IRELAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 601 IRELAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 602 IRELAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 603 IRELAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 604 POLAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 605 POLAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 606 POLAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 607 POLAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 608 POLAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 609 POLAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 610 POLAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 611 POLAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 612 POLAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 613 POLAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 614 POLAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 615 POLAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 616 POLAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 617 POLAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 618 POLAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 619 POLAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 620 POLAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 621 POLAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 622 POLAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 623 POLAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 624 POLAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 625 POLAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 626 POLAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 627 POLAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 628 POLAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 629 POLAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 630 POLAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 631 POLAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 632 POLAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 633 POLAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 634 POLAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 635 POLAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 636 POLAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 637 POLAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 638 POLAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 639 POLAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 640 REST OF EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

Abbildungsverzeichnis

FIGURE 1 EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 8 EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 9 HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 10 BREAST CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN 2022 TO 2029

FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET

FIGURE 12 ESTIMATED NUMBER OF NEW CASES AND DEATHS BY VARIOUS TYPES OF CANCER WORLDWIDE, 2020

FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES

FIGURE 14 EUROPE CANCER TREATMENT MARKET: BY CANCER TYPE, 2021

FIGURE 15 EUROPE CANCER TREATMENT MARKET: BY CANCER TYPE, 2020-2029 (USD MILLION)

FIGURE 16 EUROPE CANCER TREATMENT MARKET: BY CANCER TYPE, CAGR (2022-2029)

FIGURE 17 EUROPE CANCER TREATMENT MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 18 EUROPE CANCER TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 19 EUROPE CANCER TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD MILLION)

FIGURE 20 EUROPE CANCER TREATMENT MARKET: BY TREATMENT CAGR (2022-2029)

FIGURE 21 EUROPE CANCER TREATMENT MARKET: BY TREATMENT LIFELINE CURVE

FIGURE 22 EUROPE CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 23 EUROPE CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 24 EUROPE CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 25 EUROPE CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION LIFELINE CURVE

FIGURE 26 EUROPE CANCER TREATMENT MARKET: BY END USER, 2021

FIGURE 27 EUROPE CANCER TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 28 EUROPE CANCER TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 EUROPE CANCER TREATMENT MARKET: BY END USER LIFELINE CURVE

FIGURE 30 EUROPE CANCER TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 31 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 32 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 EUROPE CANCER TREATMENT MARKET: BY CANCER TYPE (2022-2029)

FIGURE 35 EUROPE CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)

Detaillierte Informationen anzeigen

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

Which are the major data pointers of the Europe Cancer Treatment Market?

The new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are the major data pointers of the Europe Cancer Treatment Market.

What is the Growth Rate of the Europe Cancer Treatment Market?

The Europe Cancer Treatment Market growth rate will be 11.2% by 2029.

What are the growth drivers of the Europe Cancer Treatment Market?

The high prevalence of cancer and rising government initiatives are the growth drivers of the Europe Cancer Treatment Market.

What are the factors on which the Europe Cancer Treatment Market research is based on?

The cancer type, treatment, route of administration, and end user are the factors on which the Europe Cancer Treatment Market research is based.

Which are the major companies in the Europe Cancer Treatment Market?

The Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd., Clegen, AbbVie, Inc., Pfizer, Inc., and Novartis AG are the major companies in the Europe Cancer Treatment Market.

Europäischer Markt für Krebsbehandlungen – Branchentrends und Prognose bis 2029

Europäischer Markt für Krebsbehandlungen – Branchentrends und Prognose bis 2029

Europe Cancer Treatment Market

CAGR : 11.20 %

Marktanalyse und Einblicke : Europäischer Markt für Krebsbehandlungen

Marktumfang und Marktgröße für Krebsbehandlungen in Europa

Europa: Markt für Krebsbehandlungen – Länderebene-Analyse

Wettbewerbsumfeld und Marktanteilsanalyse für Krebsbehandlungen in Europa

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Berichte

Markteinblicke

Unterstützung

Lösungen

Europäischer Markt für Krebsbehandlungen – Branchentrends und Prognose bis 2029

Europäischer Markt für Krebsbehandlungen – Branchentrends und Prognose bis 2029

Europe Cancer Treatment Market

CAGR : 11.20 %

Marktanalyse und Einblicke : Europäischer Markt für Krebsbehandlungen

Marktumfang und Marktgröße für Krebsbehandlungen in Europa

Europa: Markt für Krebsbehandlungen – Länderebene-Analyse

Wettbewerbsumfeld und Marktanteilsanalyse für Krebsbehandlungen in Europa

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Verwandte Seiten durchsuchen